All In Biotech

NDA 216962 · Abbvie

Vyalev

Foscarbidopa, Foslevodopa · Subcutaneous

Orphan

Last checked: Nov 19, 2026Latest source record: Mar 19, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Oct 16, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

4

3 Phase 3, 0 recruiting

FAERS reports

8,815

7,502 serious, 1,446 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 19, 2026.

VYALEV is indicated for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD). VYALEV is a combination of foscarbidopa (an aromatic amino acid decarboxylation inhibitor) and foslevodopa (an aromatic amino acid) indicated for the treatment of motor fluctuations in adults with advanced Parkinson’s disease. ( 1 )

Mechanism: VYALEV is a prodrug combination of foscarbidopa (carbidopa-4´-monophosphate) and foslevodopa (levodopa-4´-monophosphate). Foscarbidopa and foslevodopa are converted in vivo to carbidopa and levodopa. Carbidopa When levodopa is administered orally, it is rapidly decarboxylated to dopamine in extracerebral tissues so that only a small portion of a given dose is transported unchanged to the central nervous system. Carbidopa inhibits the decarboxylation of peripheral levodopa, making more levodopa available for delivery to the brain. Levodopa Levodopa is the metabolic precursor of dopamine, does...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 16, 2024 Original approval · Type 3 - New Dosage Form and Type 4 - New Combination OrphanLetterLabelReview
1 products under this application
  • VYALEV · FOSCARBIDOPA 120MG/10ML; FOSLEVODOPA 2400MG/10ML (12MG/ML · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Foscarbidopa" as an intervention, any sponsor and status, largest first.

All 4 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • on and off phenomenon1,211
  • fall1,137
  • hallucination892
  • death758
  • dyskinesia731
  • tremor513
  • device issue488
  • general physical health deterioration465
  • mobility decreased461
  • infusion site erythema430
  • malaise412
  • asthenia397

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20181
20231
2024380
20254,254
20264,179

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 12 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.